282 related articles for article (PubMed ID: 34772733)
1. EP300 Selectively Controls the Enhancer Landscape of MYCN-Amplified Neuroblastoma.
Durbin AD; Wang T; Wimalasena VK; Zimmerman MW; Li D; Dharia NV; Mariani L; Shendy NAM; Nance S; Patel AG; Shao Y; Mundada M; Maxham L; Park PMC; Sigua LH; Morita K; Conway AS; Robichaud AL; Perez-Atayde AR; Bikowitz MJ; Quinn TR; Wiest O; Easton J; Schönbrunn E; Bulyk ML; Abraham BJ; Stegmaier K; Look AT; Qi J
Cancer Discov; 2022 Mar; 12(3):730-751. PubMed ID: 34772733
[TBL] [Abstract][Full Text] [Related]
2. Differential contribution of p300 and CBP to regulatory element acetylation in mESCs.
Martire S; Nguyen J; Sundaresan A; Banaszynski LA
BMC Mol Cell Biol; 2020 Jul; 21(1):55. PubMed ID: 32690000
[TBL] [Abstract][Full Text] [Related]
3. The BRD4 Inhibitor dBET57 Exerts Anticancer Effects by Targeting Superenhancer-Related Genes in Neuroblastoma.
Jia SQ; Zhuo R; Zhang ZM; Yang Y; Tao YF; Wang JW; Li XL; Xie Y; Li G; Wu D; Chen YL; Yu JJ; Feng CX; Li ZH; Zhou RF; Yang RD; Yang PC; Zhou B; Wan XM; Wu YM; Jiao WY; Zhou NN; Fang F; Pan J
J Immunol Res; 2022; 2022():7945884. PubMed ID: 36438198
[TBL] [Abstract][Full Text] [Related]
4. Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma.
Zeid R; Lawlor MA; Poon E; Reyes JM; Fulciniti M; Lopez MA; Scott TG; Nabet B; Erb MA; Winter GE; Jacobson Z; Polaski DR; Karlin KL; Hirsch RA; Munshi NP; Westbrook TF; Chesler L; Lin CY; Bradner JE
Nat Genet; 2018 Apr; 50(4):515-523. PubMed ID: 29379199
[TBL] [Abstract][Full Text] [Related]
5. A dynamic H3K27ac signature identifies VEGFA-stimulated endothelial enhancers and requires EP300 activity.
Zhang B; Day DS; Ho JW; Song L; Cao J; Christodoulou D; Seidman JG; Crawford GE; Park PJ; Pu WT
Genome Res; 2013 Jun; 23(6):917-27. PubMed ID: 23547170
[TBL] [Abstract][Full Text] [Related]
6. Super enhancers define regulatory subtypes and cell identity in neuroblastoma.
Gartlgruber M; Sharma AK; Quintero A; Dreidax D; Jansky S; Park YG; Kreth S; Meder J; Doncevic D; Saary P; Toprak UH; Ishaque N; Afanasyeva E; Wecht E; Koster J; Versteeg R; Grünewald TGP; Jones DTW; Pfister SM; Henrich KO; van Nes J; Herrmann C; Westermann F
Nat Cancer; 2021 Jan; 2(1):114-128. PubMed ID: 35121888
[TBL] [Abstract][Full Text] [Related]
7. Targeting p300 Addiction in CBP-Deficient Cancers Causes Synthetic Lethality by Apoptotic Cell Death due to Abrogation of MYC Expression.
Ogiwara H; Sasaki M; Mitachi T; Oike T; Higuchi S; Tominaga Y; Kohno T
Cancer Discov; 2016 Apr; 6(4):430-45. PubMed ID: 26603525
[TBL] [Abstract][Full Text] [Related]
8. HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype.
Xu M; Sun M; Zhang X; Nguyen R; Lei H; Shern JF; Thiele CJ; Liu Z
Cancer Res; 2023 Mar; 83(5):686-699. PubMed ID: 36598365
[TBL] [Abstract][Full Text] [Related]
9. P300 Interacted With N-Myc and Regulated Its Protein Stability via Altering Its Post-Translational Modifications in Neuroblastoma.
Cheng C; He T; Chen K; Cai Y; Gu Y; Pan L; Duan P; Wu Y; Wu Z
Mol Cell Proteomics; 2023 Mar; 22(3):100504. PubMed ID: 36708875
[TBL] [Abstract][Full Text] [Related]
10. Bromodomain inhibition of the coactivators CBP/EP300 facilitate cellular reprogramming.
Ebrahimi A; Sevinç K; Gürhan Sevinç G; Cribbs AP; Philpott M; Uyulur F; Morova T; Dunford JE; Göklemez S; Arı Ş; Oppermann U; Önder TT
Nat Chem Biol; 2019 May; 15(5):519-528. PubMed ID: 30962627
[TBL] [Abstract][Full Text] [Related]
11. Discovery and Characterization of Active CBP/EP300 Degraders Targeting the HAT Domain.
Cheng-Sánchez I; Gosselé KA; Palaferri L; Kirillova MS; Nevado C
ACS Med Chem Lett; 2024 Mar; 15(3):355-361. PubMed ID: 38505842
[TBL] [Abstract][Full Text] [Related]
12. Adenovirus E1A Activation Domain Regulates H3 Acetylation Affecting Varied Steps in Transcription at Different Viral Promoters.
Hsu E; Pennella MA; Zemke NR; Eng C; Berk AJ
J Virol; 2018 Sep; 92(18):. PubMed ID: 29976669
[TBL] [Abstract][Full Text] [Related]
13.
Maeshima R; Moulding D; Stoker AW; Hart SL
Nucleic Acid Ther; 2020 Aug; 30(4):237-248. PubMed ID: 32240058
[TBL] [Abstract][Full Text] [Related]
14. Targeted degradation of the enhancer lysine acetyltransferases CBP and p300.
Vannam R; Sayilgan J; Ojeda S; Karakyriakou B; Hu E; Kreuzer J; Morris R; Herrera Lopez XI; Rai S; Haas W; Lawrence M; Ott CJ
Cell Chem Biol; 2021 Apr; 28(4):503-514.e12. PubMed ID: 33400925
[TBL] [Abstract][Full Text] [Related]
15. Regulation of Tumor-Associated Myeloid Cell Activity by CBP/EP300 Bromodomain Modulation of H3K27 Acetylation.
de Almeida Nagata DE; Chiang EY; Jhunjhunwala S; Caplazi P; Arumugam V; Modrusan Z; Chan E; Merchant M; Jin L; Arnott D; Romero FA; Magnuson S; Gascoigne KE; Grogan JL
Cell Rep; 2019 Apr; 27(1):269-281.e4. PubMed ID: 30943407
[TBL] [Abstract][Full Text] [Related]
16. Enhancer hijacking determines extrachromosomal circular MYCN amplicon architecture in neuroblastoma.
Helmsauer K; Valieva ME; Ali S; Chamorro González R; Schöpflin R; Röefzaad C; Bei Y; Dorado Garcia H; Rodriguez-Fos E; Puiggròs M; Kasack K; Haase K; Keskeny C; Chen CY; Kuschel LP; Euskirchen P; Heinrich V; Robson MI; Rosswog C; Toedling J; Szymansky A; Hertwig F; Fischer M; Torrents D; Eggert A; Schulte JH; Mundlos S; Henssen AG; Koche RP
Nat Commun; 2020 Nov; 11(1):5823. PubMed ID: 33199677
[TBL] [Abstract][Full Text] [Related]
17. Discovery of DS-9300: A Highly Potent, Selective, and Once-Daily Oral EP300/CBP Histone Acetyltransferase Inhibitor.
Kanada R; Kagoshima Y; Suzuki T; Nakamura A; Funami H; Watanabe J; Asano M; Takahashi M; Ubukata O; Suzuki K; Aikawa T; Sato K; Goto M; Setsu G; Ito K; Kihara K; Kuroha M; Kohno T; Ogiwara H; Isoyama T; Tominaga Y; Higuchi S; Naito H
J Med Chem; 2023 Jan; 66(1):695-715. PubMed ID: 36572866
[TBL] [Abstract][Full Text] [Related]
18. Genomic profile of MYCN non-amplified neuroblastoma and potential for immunotherapeutic strategies in neuroblastoma.
Lee E; Lee JW; Lee B; Park K; Shim J; Yoo KH; Koo HH; Sung KW; Park WY
BMC Med Genomics; 2020 Nov; 13(1):171. PubMed ID: 33172452
[TBL] [Abstract][Full Text] [Related]
19.
Zimmerman MW; Liu Y; He S; Durbin AD; Abraham BJ; Easton J; Shao Y; Xu B; Zhu S; Zhang X; Li Z; Weichert-Leahey N; Young RA; Zhang J; Look AT
Cancer Discov; 2018 Mar; 8(3):320-335. PubMed ID: 29284669
[TBL] [Abstract][Full Text] [Related]
20. Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma.
Hallett RM; Seong AB; Kaplan DR; Irwin MS
Mol Oncol; 2016 Nov; 10(9):1461-1472. PubMed ID: 27599694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
